Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.83 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15942904 | 0.84 | KDM4E (0.87) | KDM4EHSD17B10 | |
| SCHEMBL16948555 | 0.84 | KDM4E (0.59) | KDM4EMEN1KMT2A | |
| SCHEMBL13592713 | 0.83 | KDM4E (0.58) | KDM4EHSD17B10MEN1KMT2A | |
| SCHEMBL14198102 | 0.83 | KDM4E (0.57) | KDM4EKMT2A | |
| SCHEMBL15829104 | 0.79 | KDM4E (0.77) | KDM4EHSD17B10 | |
| SCHEMBL11231874 | 0.79 | KDM4E (0.53) | KDM4ETSHRHSD17B10 | |
| SCHEMBL16948554 | 0.79 | KDM4E (0.53) | KDM4EHSD17B10MEN1KMT2A | |
| SCHEMBL5360755 | 0.79 | KDM4E (0.70) | KDM4EHSD17B10 | |
| SCHEMBL11235646 | 0.79 | KDM4E (0.53) | KDM4EKMT2A | |
| SCHEMBL13882631 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | KDM4E 990/4885TSHR 3626/4885HSD17B10 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.